Tradestie Institutional Equity Comparison Engine
BMRA vs CODX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BMRA Overall Edge
BMRA Captures Institutional Edge (3โ1 Pillars ยท 4โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Biomerica Inc (BMRA) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CODX counters with relative strength in Valuation. Fundamentally, BMRA trades at N/M Forward P/E with -125.2% operating margin (-8.3% YoY revenue) versus CODX at 15.4x Forward P/E and -3415.8% operating margin (+94.6% YoY). In options structure, BMRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CODX sits in BREAKDOWN (50th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CODX
BMRA N/M vs CODX 15.4x Fwd P/E
Growth & Margin Winner
BMRA
Op Margin -125.2% vs -3415.8% ยท YoY -8.3% vs +94.6%
Momentum & Technical Winner
BMRA
1Y -45.6% vs -45.5% ยท 52W Pos 5% vs 0%
Options & Structure Winner
BMRA
UNCLASSIFIED (N/A IV) vs BREAKDOWN (50th %ile IV)
BMRA
NASDAQ
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.36
+0.0% 1D
Market Cap
$6.0M
1M Return
-26.49%
1Y Return
-45.6%
Forward P/E
N/M
Unified AI Score
44.5 / 100
HOLD
Tech 40.0
Fund 47.0
Flow 50.0
Mom 44.0
CODX
NASDAQ
Co-Diagnostics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.23
-11.68% 1D
Market Cap
$2.3M
1M Return
-65.08%
1Y Return
-45.54%
Forward P/E
15.4x
Unified AI Score
51.6 / 100
HOLD
Tech 55.0
Fund 54.0
Flow 66.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
BMRA -45.6%
CODX -45.54%
Spread: +7.0 pp (CODX Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | BMRA Revenue | CODX Revenue | BMRA Op. Margin | CODX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $10M | $0M | -46.4% | -2741.6% | BMRA |
| FY2020 | $10M | $70M | -41.0% | 55.9% | CODX |
| FY2021 | $10M | $100M | -104.2% | 47.1% | CODX |
| FY2022 | $20M | $30M | -24.0% | -78.8% | BMRA |
| FY2023 | $10M | $10M | -135.3% | -626.9% | BMRA |
| FY2024 | $10M | $0M | -117.6% | -1023.7% | BMRA |
| FY2025 | $10M | $0M | -96.7% | -8058.8% | BMRA |
| FY2026 | $0M | N/A | -119.5% | N/A | BMRA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BMRA | CODX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $6.0M | $2.3M | Larger Scale | Tie |
| Trailing P/E Ratio Valuation | N/M | 15.4x | Lower Multiple | CODX |
| Forward P/E Ratio Valuation | N/M | 15.4x | Lower Multiple | CODX |
| Revenue Growth (YoY) Growth | -8.3% | +94.6% | Higher Growth | CODX |
| Operating Margin (TTM) Profitability | -125.2% | -3415.8% | Higher Margin | BMRA |
| Net Profit Margin Profitability | -115.5% | 0.0% | Higher Margin | CODX |
| Return on Equity (ROE) Capital Efficiency | -113.8% | -192.8% | Higher ROE | BMRA |
| 52-Week Range Position Momentum | 5% ($1โ$3) | 0% ($0โ$14) | Stronger Trend | BMRA |
| Beta / 30D Volatility Risk Regime | 0.67ฮฒ ยท 62% Vol | 2.93ฮฒ ยท 148% Vol | Lower Realized Risk | BMRA |
| Unified Institutional Score Composite Signal | 44.5 / 100 (HOLD) | 51.6 / 100 (HOLD) | Higher Composite | CODX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full BMRA vs CODX Buy Guide
BMRA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
CODX
BREAKDOWN
173d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
50th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither BMRA nor CODX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.